We’re thrilled to announce that Dr. Sigurdsson’s distinguished research team conducted a cutting-edge study on the efficacy and safety profile of sdAbs with the help of our scientists, who provide leading Custom Single Domain (VHH) Antibody Services. The Sigurdsson Team focused on immunoglobulin G (IgG) subclasses/subtypes in targeting pathological tau protein in tauopathies. The study utilized two single domain antibodies (sdAbs) developed from a llama immunized with tau proteins.
Their research findings demonstrate that tau antibodies with effector function are both safe and more effective at clearing pathological tau than effectorless antibodies. Furthermore, the study revealed that tau antibodies have the potential to provide valuable insights into tau pathogenesis, with some antibodies potentially aggravating tau pathology (See publication).
These groundbreaking findings represent a significant step forward in the understanding of tauopathies, including Alzheimer’s disease, and hold enormous promise for developing new treatments.
“The sdAbs that we made using the services of ProSci continue to be important for our ongoing studies to clarify the pathogenesis of various neurodegenerative diseases and for developing therapies and diagnostic markers for these diseases.” -Dr. Einar Sigurdsson
We are excited to witness how researchers and scientists are expanding the applications and utility of single domain antibodies in their studies. The unique characteristics of single domain antibodies open many opportunities for researchers and scientists to develop diagnostics and therapeutics.
Visit our website to learn more about how our CAS services can advance your research endeavors.
ProSci Single Domain Antibodies for Research
Are you looking for ready-to-go single domain antibodies for your next research discovery? Visit the complete catalog of ProSci single domain antibodies to find the right tool for you!
ProSci offers single domain antibodies against immune checkpoint targets such as LAG3, PD-L1, PD-1, and TIGIT, as well as single domain antibodies against the SARS-CoV-2 spike protein.